NCT02831257View on ClinicalTrials.gov

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

PHASE2CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

October 1, 2020

Conditions

Neurofibromatosis 2Meningioma

Interventions

DRUG

AZD2014

Trial Locations (2)

02115

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

collaborator

United States Department of Defense

FED

lead

Massachusetts General Hospital

OTHER